Bharat Biotech and GSK have announced a progressive price reduction of their malaria vaccine (RTS,S/Mosquirix), aiming for under $5 per dose by 2028—over half the current price. Production scalability and streamlined processes will gradually transfer manufacturing to Bharat Biotech, with GSK continuing key components supply. The move is backed by Gavi to support vaccine delivery in low-income regions. WHO-approved vaccine, launched in 2022, is currently being rolled out in 12 African countries this year. The price cut is expected to expand global access and tackle malaria-related mortality effectively .
